Asset
OXIGLUTATIONE DISODIUM
Cellectar Biosciences Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00345540 | phase2 | completed | 2006-07-01 | 2008-05-01 | Cellectar Biosciences, Inc. | Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer |
| NCT00347412 | phase3 | completed | 2006-11-01 | 2010-01-01 | Cellectar Biosciences, Inc. | Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer |
FDA applications (0)
This company has no applications containing this asset.